ABSTRACT
Introducción En España, el tratamiento farmacológico de la enfermedad pulmonar obstructiva crónica se basa en la Global Initiative for Chronic Obstructive Lung Disease (GOLD) y la Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC). El objetivo principal de este estudio fue evaluar la concordancia entre los tratamientos de inicio asignados por GOLD y GesEPOC. Material y métodos Estudio de simulación. Se emplearon las siguientes variables: FEV1%, exacerbaciones, disnea inicial, eosinofilia en sangre, antecedente de asma y grado de reversibilidad en la prueba broncodilatadora. Cuatro neumólogos clasificaron/asignaron un tratamiento a cada paciente (2 de ellos según GOLD y 2 según GesEPOC). Se calculó el coeficiente Kappa de Cohen global. Resultados Se incluyeron 467 pacientes. La concordancia entre el tratamiento recomendado por GOLD y GesEPOC fue pobre (Kappa: 0,17, IC 95%: 0,12-0,23). Conclusión Existe una pobre concordancia entre GOLD y GesEPOC a la hora de iniciar tratamiento en los pacientes con enfermedad pulmonar obstructiva crónica (AU)
Introduction Pharmacological treatment of chronic obstructive pulmonary disease in Spain is usually chosen according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) or Spanish guidelines for chronic obstructive pulmonary disease (GesEPOC). The main objective of this study was to evaluate the degree of concordance between treatment for newly diagnosed chronic obstructive pulmonary disease patients according to GOLD and GesEPOC. Material and methods Simulation study. The following variables were used: FEV1%, exacerbations, dyspnoea at first evaluation, blood eosinophilia, personal history of asthma, and degree of bronchodilator reversibility. Four investigators classified and assigned a treatment to each patient (2 using GOLD criteria and the other 2 using GesEPOC). Global Kappa index was calculated. Results The database included 467 patients. Agreement between treatment decided using GOLD and GesEPOC was poor (Kappa: 0.17, 95% CI: 0.12-0.23). Conclusion There is a poor agreement between GOLD and GesEPOC recommendations for initial chronic obstructive pulmonary disease treatment (AU)
Subject(s)
Humans , Middle Aged , Aged , Pulmonary Disease, Chronic Obstructive/therapy , Practice Guidelines as TopicABSTRACT
INTRODUCTION: Pharmacological treatment of chronic obstructive pulmonary disease in Spain is usually chosen according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) or Spanish guidelines for chronic obstructive pulmonary disease (GesEPOC). The main objective of this study was to evaluate the degree of concordance between treatment for newly diagnosed chronic obstructive pulmonary disease patients according to GOLD and GesEPOC. MATERIAL AND METHODS: Simulation study. The following variables were used: FEV1%, exacerbations, dyspnoea at first evaluation, blood eosinophilia, personal history of asthma, and degree of bronchodilator reversibility. Four investigators classified and assigned a treatment to each patient (2 using GOLD criteria and the other 2 using GesEPOC). Global Kappa index was calculated. RESULTS: The database included 467 patients. Agreement between treatment decided using GOLD and GesEPOC was poor (Kappa: 0.17, 95% CI: 0.12-0.23). CONCLUSION: There is a poor agreement between GOLD and GesEPOC recommendations for initial chronic obstructive pulmonary disease treatment.
